Leukemia
Results from the 4-year follow-up of the ELEVATE-TN study support acalabrutinib with or without immunotherapy in previously untreated patients with chronic lymphocytic leukemia. Read More ›
Being diagnosed with cancer and undergoing subsequent treatment can be challenging for patients and their partners, but intimacy does not have to end. Read More ›
In June 2021, the FDA approved Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn), an asparagine-specific enzyme, to be used as part of a multi-drug chemotherapy regimen for patients older than 1 month with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to asparaginase caused by E. coli infection. Read More ›
Ongoing clinical trials are poised to expand the role of acalabrutinib in treating chronic lymphocytic leukemia. Read More ›
Chronic lymphocytic leukemia can have a negative effect on patients’ quality of life, but healthcare teams may be able to minimize the impact. Read More ›
Low-dose chemoimmunotherapy may be an effective first-line therapy for certain patients with chronic lymphocytic leukemia and particular biological and genetic features. Read More ›
By keeping themselves physically and emotionally healthy, caregivers can give their loved ones the best possible support when helping to care for them. Read More ›
George Valentine was diagnosed with chronic lymphocytic leukemia in 2002. He shares some of his hard-learned tips on how to deal with a cancer diagnosis and the high costs of treatment. Read More ›
The COVID-19 pandemic has resulted in several changes in how patients with chronic lymphocytic leukemia (CLL) are treated. Read More ›